Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, at 4:15 p.m. ET as part of its Regulation D 506(c) offering and up to $5 million capital raise. The offering structure ensures no dilution to Quantum BioPharma shareholders, providing a unique investment opportunity that preserves existing shareholder value while funding expansion of the unbuzzd beverage product.
The webinar will feature Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius. These industry veterans will discuss the investment opportunity for unbuzzd, a scientifically proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. The presentation will cover leadership strategy, distribution plans, and include a question-and-answer session for potential investors.
Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry professionals with extensive experience in beverage and wellness markets. Under the licensing agreement, Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness as of March 31, 2025, and receives royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. This arrangement provides Quantum BioPharma with ongoing revenue streams without additional capital investment.
The company maintains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving its ability to leverage the underlying technology across multiple market segments. This strategic positioning allows Quantum BioPharma to benefit from both consumer wellness markets through Unbuzzd Wellness and potential pharmaceutical applications through its internal development pipeline.
Quantum BioPharma focuses on building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, positioning Lucid-MS as a potential breakthrough treatment for this challenging neurological condition.
The investor webinar represents a significant milestone in the commercialization pathway for unbuzzd, providing market validation for Quantum BioPharma's licensing strategy and technology development approach. For investors, the offering provides exposure to the rapidly growing functional beverage market while benefiting from the scientific validation and intellectual property protection developed by Quantum BioPharma. The non-dilutive nature of the capital raise to Quantum shareholders demonstrates the company's commitment to preserving shareholder value while advancing its licensed technologies to market.
Additional information about Quantum BioPharma is available through the company's newsroom at https://ibn.fm/QNTM. The upcoming investor webinar on October 30, 2025, represents a key opportunity for market participants to understand the growth potential of unbuzzd and its positioning within the broader functional beverage and wellness markets.
